NCT02296918 2025-12-19Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLAcerta Pharma BVPhase 1 Completed69 enrolled
NCT02175433 2024-11-01A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid MalignanciesAstellas Pharma IncPhase 1 Completed71 enrolled
NCT00546793 2021-08-16Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLGilead SciencesPhase 1/2 Completed32 enrolled
NCT00891137 2014-10-27Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyCellerant TherapeuticsPhase 1 Completed30 enrolled
NCT01955668 2014-06-19AZD6738 First Time in Patient Multiple Ascending Dose StudyAstraZenecaPhase 1 Completed2 enrolled
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts
NCT00126646 2010-06-22BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaMedImmune LLCPhase 1 Completed24 enrolled